Skip to Main Content

Protagonist Therapeutics, Inc

PTGX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
PTGX Income Statement
PTGX Balance Sheet
PTGX Cash Flow

Recent trades of PTGX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
PTGX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
PTGX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
PTGX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by PTGX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jan. 30, 2024
  • Patent Title: Α4β7 thioether peptide dimer antagonists Dec. 12, 2023
  • Patent Title: Hepcidin analogues and uses thereof Nov. 07, 2023
  • Patent Title: Conjugated hepcidin mimetics Sep. 12, 2023
  • Patent Title: Analogues of hepcidin mimetics with improved in vivo half lives Oct. 18, 2022
  • Patent Title: Α4α7 peptide monomer and dimer antagonists Sep. 07, 2021
  • Patent Title: Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Jun. 22, 2021
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Mar. 09, 2021
  • Patent Title: Opioid agonist peptides and uses thereof Aug. 04, 2020
  • Patent Title: Hepcidin analogues and uses thereof Dec. 10, 2019
  • Patent Title: Hepcidin analogues and uses thereof Oct. 15, 2019
  • Patent Title: Methods for synthesizing α4β7 peptide antagonists Sep. 10, 2019
  • Patent Title: Cyclic monomer and dimer peptides having integrin antagonist activity May. 28, 2019
  • Patent Title: Opioid agonist peptides and uses thereof May. 07, 2019
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Feb. 05, 2019
  • Patent Title: Α4β7 thioether peptide dimer antagonists Aug. 28, 2018
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 31, 2018
  • Patent Title: Hepcidin analogues and uses thereof Jul. 24, 2018
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 17, 2018
  • Patent Title: Hepcidin analogues and uses thereof Nov. 21, 2017
  • Patent Title: Α4β7 peptide monomer and dimer antagonists Nov. 07, 2017
  • Patent Title: A4b7 integrin thioether peptide antagonists Jul. 25, 2017
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Apr. 18, 2017
  • Patent Title: Α4β7 peptide dimer antagonists Mar. 01, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of PTGX in WallStreetBets Daily Discussion

PTGX News

Recent insights relating to PTGX

CNBC Recommendations

Recent picks made for PTGX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PTGX

PTGX Top Shareholders
Shareholder
Shares Held
PTGX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

PTGX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view PTGX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top